Reports - Psychedelic Drugs Market
HealthcarePsychedelic Drugs Market
Psychedelic Drugs Market Valuation and Growth Forecast 2025-2035 by Source (Synthetic, Natural) by Therapeutic Drugs (Psilocybin, LSD, MDMA, DMT, Ketamine) by Route of Administration (Oral, Injectable, Inhalation) by Indication (Alzheimer Dementia, Anorexia and Obesity, Anxiety & Depressive Disorders, Cluster Headaches, Obsessive Compulsive Disorders, Personality Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorders, Terminal Cancer Distress) by Distribution Channel (Hospital Pharmacies (Dominating 57.3%), Retail Pharmacies, Online Pharmacies) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Psychedelic Drugs Market - Segment Analysis
1. Overview
2. Global Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. Global Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. Global Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. Global Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. Global Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. Global Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
8. Global Psychedelic Drugs Market - by region
8.1. North America
8.2. Europe
8.3. Asia Pacific
8.4. Latin America
8.5. Middle East & Africa
9. Market comparative analysis
Chapter 4 North America Psychedelic Drugs Market - Segment Analysis
1. Overview
2. North America Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. North America Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. North America Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. North America Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. North America Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. North America Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
Chapter 5 Europe Psychedelic Drugs Market - Segment Analysis
1. Overview
2. Europe Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. Europe Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. Europe Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. Europe Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. Europe Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. Europe Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
Chapter 6 Asia Pacific Psychedelic Drugs Market - Segment Analysis
1. Overview
2. Asia Pacific Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. Asia Pacific Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. Asia Pacific Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. Asia Pacific Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. Asia Pacific Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. Asia Pacific Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
Chapter 7 Latin America Psychedelic Drugs Market - Segment Analysis
1. Overview
2. Latin America Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. Latin America Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. Latin America Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. Latin America Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. Latin America Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. Latin America Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
Chapter 8 Middle East & Africa Psychedelic Drugs Market - Segment Analysis
1. Overview
2. Middle East & Africa Psychedelic Drugs Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Psychedelic Drugs Market - by Source
3.1. By Synthetic
3.2. By Natural
4. Middle East & Africa Psychedelic Drugs Market - by Therapeutic Drugs
4.1. By Psilocybin
4.2. By LSD
4.3. By MDMA
4.4. By DMT
4.5. By Ketamine
5. Middle East & Africa Psychedelic Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Inhalation
6. Middle East & Africa Psychedelic Drugs Market - by Indication
6.1. By Alzheimer Dementia
6.2. By Anorexia and Obesity
6.3. By Anxiety & Depressive Disorders
6.4. By Cluster Headaches
6.5. By Obsessive Compulsive Disorders
6.6. By Personality Disorder
6.7. By Post-Traumatic Stress Disorder
6.8. By Substance Abuse Disorders
6.9. By Terminal Cancer Distress
7. Middle East & Africa Psychedelic Drugs Market - by Distribution Channel
7.1. By Hospital Pharmacies (Dominating 57.3%)
7.2. By Retail Pharmacies
7.3. By Online Pharmacies
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Atai Life Sciences NV
2. Compass Pathways PLC
3. MindMed Inc
4. Takeda Pharmaceutical Company Limited
5. Pfizer Inc.
6. Alkermes
7. Celon Pharma S.A
8. Seelos Therapeutics Inc.
9. HAVN Life Sciences Inc.
10. Numinus Wellness Inc.
11. Eli Lilly and Company
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By